KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $73.4 million.

  • Sarepta Therapeutics' Other Non-Current Assets rose 37104.44% to $73.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.4 million, marking a year-over-year increase of 37104.44%. This contributed to the annual value of $79.9 million for FY2024, which is 4157.02% down from last year.
  • Sarepta Therapeutics' Other Non-Current Assets amounted to $73.4 million in Q3 2025, which was up 37104.44% from $83.1 million recorded in Q2 2025.
  • Over the past 5 years, Sarepta Therapeutics' Other Non-Current Assets peaked at $293.1 million during Q3 2022, and registered a low of $15.6 million during Q1 2024.
  • Moreover, its 5-year median value for Other Non-Current Assets was $162.4 million (2023), whereas its average is $157.9 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first tumbled by 9040.63% in 2024, then skyrocketed by 41704.86% in 2025.
  • Over the past 5 years, Sarepta Therapeutics' Other Non-Current Assets (Quarter) stood at $292.9 million in 2021, then crashed by 44.37% to $163.0 million in 2022, then decreased by 16.08% to $136.8 million in 2023, then tumbled by 41.57% to $79.9 million in 2024, then decreased by 8.17% to $73.4 million in 2025.
  • Its last three reported values are $73.4 million in Q3 2025, $83.1 million for Q2 2025, and $80.6 million during Q1 2025.